Patents Examined by Lei Yao
  • Patent number: 12037647
    Abstract: Provided herein are methods of detecting pancreatic cancer in a subject, the method comprising measuring in a sample from the subject a level of CA19-9 polysaccharide relative to a reference, and a level of a polynucleotide or polypeptide of at least one marker selected from the group consisting of: OPN, MIA, CEACAM-1, MIC-1, SPON1, HSP27, POSTN, and LGALS3BP relative to a reference, wherein an increased level of the CA19-9 polysaccharide relative to a reference and an increased level of the polynucleotide or polypeptide relative to a reference indicates presence of pancreatic cancer in the subject.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: July 16, 2024
    Assignee: The Johns Hopkins University
    Inventors: Jin Song, Zhen Zhang, Daniel Wan-yui Chan
  • Patent number: 12018066
    Abstract: The invention provides antibodies that specifically bind the SARS-CoV-2 receptor binding domain. The antibodies are useful in treating SARS-CoV-2 virus infection and in diagnostic methods, agents, and kits thereof.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: June 25, 2024
    Assignee: TRIAD NATIONAL SECURITY, LLC
    Inventors: Antonietta Maria Lillo, Nileena Velappan, Geoffrey S. Waldo
  • Patent number: 12013397
    Abstract: A method of determining a prognosis for cancer in a subject and/or a subject with cancer includes measuring a level of proteolytically cleaved extracellular fragments of an immunoglobulin (Ig) superfamily cell adhesion molecule that is expressed by cancer cells obtained from the subject to determine at least one of prognosis for the cancer, the subject's survival, or responsiveness of the cancer to anti-cancer treatment.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: June 18, 2024
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventor: Susann Brady-Kalnay
  • Patent number: 11999774
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: June 4, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11987641
    Abstract: Disclosed herein are antibodies or antigen binding fragments thereof that bind prostate specific membrane antigen (PSMA), polynucleotides, vectors, host cells, radioconjugates, antibody drug conjugates and methods of treating cancer using the same.
    Type: Grant
    Filed: August 25, 2022
    Date of Patent: May 21, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Shalom Goldberg, Donna Klein, Neeraj Kohli, Theresa Marie McDevitt, Steven J. Orcutt
  • Patent number: 11981733
    Abstract: Provided are a LAG-3 antibody, an antigen-binding fragment thereof, and a pharmaceutical application thereof. Further, provided are a chimeric antibody comprising a CDR of the LAG-3 antibody, a humanized antibody, a pharmaceutical composition comprising the LAG-3 antibody and the antigen-binding fragment thereof, and an application of the pharmaceutical composition as an antineoplastic drug. Particularly, provided is an application of a humanized LAG-3 antibody in preparation of drugs for treatment of diseases involving immune cells.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: May 14, 2024
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Zhuoxiao Cao, Yayuan Fu, Qiyue Hu, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • Patent number: 11981737
    Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: May 14, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jens Fischer, Meher Majety, Stefan Dengl, Georg Tiefenthaler, Stefan Klostermann, Claudia Kirstenpfad, Esther Koenigsberger, Francesca Ros
  • Patent number: 11980606
    Abstract: The present disclosure relates to treatment of central nervous system (CNS) cancers (e.g., malignant glioma, glioblastoma, or CNS-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: May 14, 2024
    Assignee: Celgene International II Sàrl
    Inventors: Mohit Trikha, Nancy Levin, Ann Maclaren
  • Patent number: 11981748
    Abstract: In one aspect, the present invention provides methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from, or at risk for developing, an angiogenesis-dependent disease or condition, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis. In some embodiments of these aspects of the invention, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: May 14, 2024
    Assignees: Omeros Corporation, University of Leicester
    Inventors: Gregory A. Demopulos, Hans-Wilhelm Schwaeble, Thomas Dudler, Larry Tjoelker
  • Patent number: 11959918
    Abstract: The present invention relates to a method of diagnosing bladder cancer in an individual. Further, the present invention relates to a method of determining the course of bladder cancer in an individual. Furthermore, the present invention relates to a kit for diagnosing bladder cancer in an individual or determining the course of bladder cancer in an individual.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: April 16, 2024
    Assignee: OTTO-VON-GUERICKE-UNIVERSITÄT MAGDEBURG
    Inventors: Johannes Haybäck, Jeton Luzha
  • Patent number: 11939366
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: March 26, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11939378
    Abstract: The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: March 26, 2024
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Lieping Chen, Scott E. Strome, Eugene D. Kwon
  • Patent number: 11932678
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: March 19, 2024
    Assignee: Immatics Biotechnologies GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11912754
    Abstract: The present application provides an antibody fusion protein comprising a vascular endothelial growth factor receptor (VEGFR) fused to the C-terminus of the antibody light chain. Also provided are methods of making and using these antibody fusion proteins.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: February 27, 2024
    Assignee: IMMUNOWAKE INC.
    Inventor: Xiaoyun Wu
  • Patent number: 11912768
    Abstract: The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against CTLA4. In particular, the present invention discloses a CTLA4 binding protein and the use thereof, especially the use for treating and/or preventing CTLA4 relevant diseases such as tumor.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: February 27, 2024
    Assignees: SUZHOU ALPHAMAB CO., LTD., XITIAN ZHANG, XIN ZHANG
    Inventors: Ting Xu, Xiaoxiao Wang, Jie Li, Haiyan Wu, Li Gao, Qian Chu, Yu Bai
  • Patent number: 11903968
    Abstract: The invention pertains to the field of adoptive cell immunotherapy. It provides with engineered immune cells comprising genetic alteration into genes which are involved into immune functions downregulation, especially in response to environment signals such as nutrients depletion. Such method allows the production of more potent immune cells in the context of tumors' microenvironment.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: February 20, 2024
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, Anne-Sophie Gautron, Laurent Poirot, Julien Valton
  • Patent number: 11879006
    Abstract: Disclosed herein is a recombinant antibody exhibiting binding affinity and/or neutralizing activity to porcine epidemic diarrhea virus (PEDV). According to some embodiments of the present disclosure, the PEDV is genotype 1 (G1) or genotype 2b (G2b) PEDV. Also disclosed herein are methods of diagnosing and treating PEDV infection by use of the present recombinant antibody.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: January 23, 2024
    Assignee: Academia Sinica
    Inventors: Shang-Te Danny Hsu, Hui-Wen Chang, Chia-Yu Chang
  • Patent number: 11872270
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: January 16, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Colette Song, Linus Backert, Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
  • Patent number: 11859004
    Abstract: Provided are anti-human 4-1BB antibodies and fragments thereof with one or more structural features that are not found in a reference anti-human 4-1BB antibody, where said features may improve certain characteristics of the antibody relative to a reference antibody. Various in vitro and in vivo methods and reagents related to anti-human 4-1BB antibodies described herein are also provided. Methods include, for example, inducing T-cell proliferation, inducing T cell secretion of IFN?, as well as detection, prevention, and/or therapeutic treatment of cancer using an anti-human 4-1BB antibody or fragment thereof.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: January 2, 2024
    Assignee: EUTILEX CO., LTD.
    Inventors: Byoung S. Kwon, Seoung-Joo Lee, Young Ho Kim, Ho-Sik Oh, Joong Won Lee
  • Patent number: 11845801
    Abstract: Provided herein are IL-15 cytokine prodrugs and methods of making and using thereof.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: December 19, 2023
    Assignee: ASKGENE PHARMA, INC.
    Inventors: Yuefeng Lu, Chunxiao Yu, Jian-Feng Lu